Lihui Xu

Lihui Xu

Auto-generated profile, based on publicly available information

Lihui Xu

Palleon Pharmaceuticals, Waltham, MA, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2021 in Science China Life Sciences
Verified
Journal Article
Closed access
PDF file
DGDingbin Gong
Dingbin Gong
MTMin Tao
Min Tao
LXLihui Xu
Lihui Xu
FHFangzhou Hu
Fangzhou Hu
ZWZehong Wei
Zehong Wei
SLShaojun Liu
Shaojun Liu

16 October 2015 in Biopolymers
Verified
Journal Article
Closed access
PDF file
LXLihui Xu
Lihui Xu
Sidong TuSidong Tu
Sidong Tu
CCCongheng Chen
Congheng Chen
JZJuan Zhao
Juan Zhao
YZYuan Zhang
Yuan Zhang
PZPing Zhou
Ping Zhou


27 September 2019 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
QCQiong Chen
Qiong Chen
KCKuang Chen
Kuang Chen
SQShen-Xian Qian
Shen-Xian Qian
SWShenghai Wu
Shenghai Wu
LXLihui Xu
Lihui Xu
XWXianjun Wang
Xianjun Wang
Mucormycosis is an angioinvasive fungal infection with a high mortality rate. Patients with hematological malignancies following voriconazole therapy are at high risk from mucormycosis. Here, the present study reports on a 68‑year‑old man diagnosed with multiple myeloma and secondary myelodysplastic syndrome, who was infected with disseminated mucormycosis with cerebellum involvement confirmed by mycological culture and histopathological examination. For patients with hematological malignancies who are receiving antifungal therapy, an opportunistic infection of mucormycosis should be considered if a ‘breakthrough’ infection occurs in the predilection sites (such as the sinuses, lungs, skin, brain and gastrointestinal tract). It is difficult to diagnose mucormycosis because of the limited reliable detection methods, and because mucormycosis often presents with an acute onset and progresses rapidly, particularly in immunocompromised patients. Antifungal therapy with amphotericin B or posaconazole should be started as soon as possible considering the empirical diagnosis.

10 November 2021 in Journal for ImmunoTherapy of Cancer
Verified
Conference Paper
Open access
PDF file
LPLi Peng
Li Peng
LCLizhi Cao
Lizhi Cao
SNSujata Nerle
Sujata Nerle
RLRobert LeBlanc
Robert LeBlanc
ADAbhishek Das
Abhishek Das
JBJames Broderick
James Broderick
Background Sialoglycans, a type of glycans with a terminal sialic acid, have emerged as a critical glyco-immune checkpoint that impairs antitumor response by inhibiting innate and adaptive immunity. Upregulation of sialoglycans on tumors has been observed for decades and correlates with poor clinical outcomes across many tumor types. We previously showed that targeted desialylation of tumors using a bifunctional sialidase x antibody molecule, consisting of sialidase and a tumor-associated antigen (TAA)-targeting antibody, has led to robust single-agent efficacy in mouse tumor models. In addition to tumor cells, most immune cells present substantially more abundant sialoglycans than non-hematological healthy cells, which may also contribute to immunosuppression. Therefore, we studied the impact of immune cell desialylation and evaluated the therapeutic potential of a newly developed sialidase-Fc fusion (Bi-Sialidase), which lacks a TAA-targeting moiety and consists of engineered human neuraminidase 2 (Neu2) and human IgG1 Fc region, in preclinical mouse tumor models. Methods The first generation Neu2 variant was further optimized to improve titers and stability to constructed Bi-Sialidase. Bi-Sialidase’s desialylation potency and impact on immune responses were studied in vitro using various human immune functional assays, including T-cell activation, allogeneic mixed lymphocyte reaction, antibody-dependent cellular cytotoxicity, macrophages polarization/activation, neutrophil activation, and peripheral blood mononuclear cell (PBMC) cytokine release assays. We evaluated its antitumor efficacy in mouse tumor models. Bi-Sialidase’s safety profile was characterized by conducting rat and non-human primate (NHP) toxicology studies. Results The optimized Bi-Sialidase achieved a titer of 2.5 g/L from a 15-day fed-batch Chinese hamster ovary cell culture; in contrast, the wild-type and first-generation Neu2 had no production or a low titer (<0.1 g/L) under similar conditions, respectively. We demonstrated that Bi-Sialidase led to dose-dependent desialylation of immune cells and potentiated T-cell immunity, without impacting NK, macrophage, or neutrophil activation by desialylating immune cells. Activated and exhausted T cells upregulated surface sialoglycans and Bi-Sialidase-mediated desialylation reinvigorated exhausted-like T cells as measured by IFNg production. Bi-Sialidase treatment also enhanced DC priming and activation of naïve T cells by desialylating both T cells and DCs. Furthermore, Bi-Sialidase showed single-agent antitumor activity in multiple mouse tumor models, including MC38, CT26, A20, and B16F10. Importantly, Bi-Sialidase did not cause cytokine release in human PBMC assays and was tolerated to up to 100 mg/kg in rats and NHPs, demonstrating a wide safety margin. Conclusions Bi-Sialidase with an optimized Neu2 offers a novel immunomodulatory approach to enhancing T-cell immunity by desialylating immunosuppressive sialoglycans for cancer treatment.